We are proud to share the results of a phase 1 clinical trial in patients with Parkinson's disease, published in Nature Medicine. This patient study, conducted in collaboration with Vaxxinity, Inc. and the Michael J. Fox Foundation, demonstrates that UB-312 is the first drug candidate to produce a demonstrable immunological response in patients. UB-312 is a form of active immunotherapy that targets the aggregated protein α-synuclein (aSN), which plays an important role in Parkinson's disease. UB-312 not only proved to be safe and well tolerated, but also reached its target: anti-aSN antibodies were found in the cerebrospinal fluid, accompanied by a significant reduction in the concentration of aggregated aSN. These results mark a milestone in the search for new treatments for Parkinson's disease and support the further development of UB-312.
Read the publication here.
